21/05/2021 - 08:31
DBD: company visit
Valuation. DBD is trading at TTM PER 15.0x, slightly below its peers’ average of 16.0x. We think this valuation is reasonable given the potential earning growth on new cancer drug capacity.
21/05/2021 - 08:31
Valuation. DBD is trading at TTM PER 15.0x, slightly below its peers’ average of 16.0x. We think this valuation is reasonable given the potential earning growth on new cancer drug capacity.